Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

Stopped The study was terminated early due to low enrollment, this was partially related to our ability to recruit during the COVID-19 pandemic.

Conditions

• Clostridium Difficile Infection
• Clostridium Difficile Infection Recurrence

Interventions

• DRUG: Oral Vancomycin
• OTHER: Placebo

Sponsor

University of South Florida